Suppr超能文献

相似文献

1
BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas.
Haematologica. 2012 Apr;97(4):595-8. doi: 10.3324/haematol.2011.054080. Epub 2011 Nov 18.
3
Molecular and genomic aberrations in Chlamydophila psittaci negative ocular adnexal marginal zone lymphomas.
Am J Hematol. 2013 Sep;88(9):730-5. doi: 10.1002/ajh.23490. Epub 2013 Jul 23.
4
Mutation analysis of NF-κB signal pathway-related genes in ocular MALT lymphoma.
Int J Clin Exp Pathol. 2012;5(5):436-41. Epub 2012 May 23.
5
Nuclear factor-κB dysregulation in splenic marginal zone lymphoma: new therapeutic opportunities.
Haematologica. 2012 May;97(5):638-40. doi: 10.3324/haematol.2011.058362.
6
Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing.
Clin Cancer Res. 2015 Sep 15;21(18):4174-4183. doi: 10.1158/1078-0432.CCR-14-2759. Epub 2015 Mar 16.
7
NF-κB deregulation in splenic marginal zone lymphoma.
Semin Cancer Biol. 2016 Aug;39:61-7. doi: 10.1016/j.semcancer.2016.08.002. Epub 2016 Aug 5.
8
Splenic marginal zone lymphoma.
Best Pract Res Clin Haematol. 2017 Mar-Jun;30(1-2):56-64. doi: 10.1016/j.beha.2016.09.005. Epub 2016 Nov 5.
9
A20 inactivation in ocular adnexal MALT lymphoma.
Haematologica. 2012 Jun;97(6):926-30. doi: 10.3324/haematol.2010.036798. Epub 2011 Dec 29.

引用本文的文献

1
From development to clinical success: the journey of established and next-generation BTK inhibitors.
Invest New Drugs. 2025 Apr;43(2):377-393. doi: 10.1007/s10637-025-01513-y. Epub 2025 Feb 27.
2
The genomic and molecular landscape of splenic marginal zone lymphoma, biological and clinical implications.
Explor Target Antitumor Ther. 2024;5(4):877-901. doi: 10.37349/etat.2024.00253. Epub 2024 Jul 23.
4
IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies.
Front Immunol. 2023 Oct 26;14:1239082. doi: 10.3389/fimmu.2023.1239082. eCollection 2023.
5
NF-kB's contribution to B cell fate decisions.
Front Immunol. 2023 Jul 18;14:1214095. doi: 10.3389/fimmu.2023.1214095. eCollection 2023.
8
The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma.
Nat Commun. 2022 Jun 29;13(1):3750. doi: 10.1038/s41467-022-31430-0.
10
Zanubrutinib in lymphoproliferative disorders: a comprehensive review.
Ther Adv Hematol. 2022 May 27;13:20406207221093980. doi: 10.1177/20406207221093980. eCollection 2022.

本文引用的文献

1
Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma.
Blood. 2011 Nov 3;118(18):4930-4. doi: 10.1182/blood-2011-06-359166. Epub 2011 Aug 31.
2
A20, ABIN-1/2, and CARD11 mutations and their prognostic value in gastrointestinal diffuse large B-cell lymphoma.
Clin Cancer Res. 2011 Mar 15;17(6):1440-51. doi: 10.1158/1078-0432.CCR-10-1859. Epub 2011 Jan 25.
3
Oncogenically active MYD88 mutations in human lymphoma.
Nature. 2011 Feb 3;470(7332):115-9. doi: 10.1038/nature09671. Epub 2010 Dec 22.
4
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma.
Haematologica. 2010 Oct;95(10):1792-6. doi: 10.3324/haematol.2010.025437. Epub 2010 May 29.
5
Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas.
Curr Clin Pharmacol. 2010 May;5(2):74-81. doi: 10.2174/157488410791110751.
7
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Nature. 2010 Jan 7;463(7277):88-92. doi: 10.1038/nature08638.
8
A20 is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma.
Leukemia. 2010 Feb;24(2):483-7. doi: 10.1038/leu.2009.234. Epub 2009 Nov 12.
9
The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology.
Trends Immunol. 2009 Aug;30(8):383-91. doi: 10.1016/j.it.2009.05.007. Epub 2009 Jul 28.
10
TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas.
Blood. 2009 Sep 17;114(12):2467-75. doi: 10.1182/blood-2008-12-194852. Epub 2009 Jul 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验